Novartis will acquire the CNS disorder drug developer after backing its series B round in late 2018, also providing an exit for Access Industries.

Neurodegenerative disease management platform Octave Bioscience has now raised more than $48m in total, Blue Venture Fund and Echo Health Ventures backing its latest round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Alphabet was among the investors in the latest round for life sciences spinoff Verily, which has now disclosed $2.5bn in funding across three rounds.

Ten University of California startups are hoping to open 2021 with a bang by securing one of two $50,000 prizes at the GCV Digital Forum next month.

Biopharmaceutical company Origenis helped form the neurological and immunological disease drug developer, which has revealed series A and B funding.

The clinical data management platform boosted its total funding to $30m in a Centene-led series B round featuring Optum Ventures.

Kaiser Foundation Hospitals and Lilly Asia Ventures backed a round for the pharmaceutical research services provider that was led by Fidelity.

Novo's Repair Impact Fund and Sanofi Ventures were among the investors in a $57.6m round that will fund work on MinervaX's group B Streptococcus vaccine.

General Electric's healthcare technology subsidiary is partnering Wayra UK on a scheme focusing on artificial intelligence-equipped healthtech startups.